Trade

with

Delcath Systems Inc
(NASDAQ: DCTH)
AdChoices
1.74
-0.01
-0.57%
After Hours :
-
-
-

Open

1.74

Previous Close

1.75

Volume (Avg)

7.96k (86.01k)

Day's Range

1.73-1.75

52Wk Range

1.70-6.72

Market Cap.

16.45M

Dividend Rate ( Yield )

-

Beta

2.46

Shares Outstanding

9.45M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 790.00k

    • Net Income

    • -30.32M

    • Market Cap.

    • 16.45M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -2,255.05

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.46

    • Forward P/E

    • -

    • Price/Sales

    • 15.17

    • Price/Book Value

    • 0.65

    • Price/Cash flow

    • -0.70

      • EBITDA

      • -29.12M

      • Return on Capital %

      • -62.73

      • Return on Equity %

      • -75.12

      • Return on Assets %

      • -62.73

      • Book Value/Share

      • 2.66

      • Shares Outstanding

      • 9.45M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 17.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -0.10

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -18.60

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 73.09

            • 64.72

            • Pre-Tax Margin

            • -2,255.05

            • 13.77

            • Net Profit Margin

            • -2,255.05

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 5.35

              • 1.52

              • Quick Ratio

              • 5.08

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.24

              • 1.91

              • Book Value/Share

              • 2.66

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -0.65

                • 65.79

                • P/E Ratio 5-Year High

                • -97.95

                • 237.47

                • P/E Ratio 5-Year Low

                • -0.63

                • 19.71

                • Price/Sales Ratio

                • 15.27

                • 3.69

                • Price/Book Value

                • 0.66

                • 3.46

                • Price/Cash Flow Ratio

                • -0.70

                • 22.12

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -75.12

                    (-152.90)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -62.73

                    (-103.60)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -75.12

                    (-153.10)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • 0.34

                  • 1.80

                  • Asset Turnover

                  • 0.03

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -33.02M
                  Operating Margin
                  -4,179.62
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -0.70
                  Ownership

                  Institutional Ownership

                  11.79%

                  Top 10 Institutions

                  13.56%

                  Mutual Fund Ownership

                  2.11%

                  Float

                  99.35%

                  5% / Insider Ownership

                  27.22%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Top Alpha Overseas Equity

                  •  

                    257,400

                  • -20.19

                  • 1.11

                  • Vanguard Total Stock Mkt Idx

                  •  

                    131,189

                  • 0.00

                  • 0.56

                  • Vanguard Extended Market Index Fund

                  •  

                    44,629

                  • 0.00

                  • 0.19

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    31,941

                  • 0.00

                  • 0.16

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    7,494

                  • 0.00

                  • 0.04

                  • Vanguard Instl Total Stock Market Index

                  •  

                    4,736

                  • 0.00

                  • 0.02

                  • The Vanguard - Total Stk Mkt Idx Trust. CF

                  •  

                    1,857

                  • 0.00

                  • 0.01

                  • Fidelity® NASDAQ Composite Index® Fund

                  •  

                    357

                  • 0.00

                  • 0.00

                  • FlexShares Mstar US Mkt Factors Tilt ETF

                  •  

                    173

                  • 0.00

                  • 0.00

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Meitav DS Mutual Funds Ltd

                  •  

                    257,400

                  • -20.19%

                  • 1.11

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Speculative Growth

                  Style

                  Small Value

                  Delcath Systems, Inc., is a Delaware corporation incorporated in August 1988. The Company is a pharmaceutical and medical device company focused on oncology. The Company has directed its research efforts towards the development and c...morelinical study of the Delcath chemosaturation system. The Company’s proprietary drug/device combination product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company operates in one business segment, which is the development and commercialization of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulator...morey system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers high doses of chemotherapeutic agents directly to the liver, while limiting systemic exposure and the related side effects by filtering the blood prior to returning it to the patient. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through standard interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs and the potential for concomitant cancer therapies. The Company assembles, sterilizes and packages the Delcath chemosaturation system at its facility in Queensbury, New York and has established its European headquarters and distribution facility in Galway, Ireland. It utilizes contract manufacturers to manufacture some components of the Delcath chemosaturation system. The Delcath chemosaturation system competes with all forms of liver cancer treatments. The Delcath chemosaturation system is subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.lessless

                  Key People

                  Mr. Jennifer Simpson, PhD

                  President/CEO

                  Dr. Roger G. Stoll,PhD

                  Director/Chairman of the Board

                  Barbra C. Keck

                  Chief Accounting Officer/Controller/Vice President/CFO

                  Peter J. Graham

                  Executive VP/General Counsel/Other Corporate Officer/Other Executive Officer

                  John Purpura

                  Executive VP, Divisional

                  • Delcath Systems Inc

                  • 810 Seventh Avenue

                  • New York, NY 10019

                  • USA.Map

                  • Phone: +1 212 489 2100

                  • Fax: +1 212 489-2102

                  • delcath.com

                  Incorporated

                  1988

                  Employees

                  37

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: